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Lipoprotein(a) as a risk factor for coronary artery disease in 57.6, range 26 to 73 years). When the study was started,
hemodialysis patients. they had been already undergoing HD for an average of
Background. We studied whether lipoprotein(a) [Lp(a)] is 68.6 months (range of 2 to 268 months). In every patient,an independent risk factor for coronary artery disease (CAD)
HD was performed three times per week. The underlyingin hemodialysis (HD) patients.
diseases of 212 (79.1%) and 56 (20.9%) patients wereMethods. A serum concentration of Lp(a) was measured in
212 patients with chronic glomerulonephritis and 56 patients chronic glomerulonephritis (CGN) and diabetic nephrop-
with diabetic nephropathy (a total of 268 patients). The causes athy (DN), respectively. All patients with DN had non–
of death during five years of follow-up were studied and classi- insulin-dependent diabetes mellitus (NIDDM). Clinicalfied into either cardiovascular or noncardiovascular events.
history, physical examination, and routine laboratoryResults. The mortality of these 268 HD patients during the
tests were performed at entry. A previous history ofobservation period was 26.1%. Seventy-eight percent were due
to cardiovascular events. Those who died of cardiovascular myocardial infarction or cerebrovascular accident as well
events had significantly higher serum Lp(a) levels than those as angina pectoris was considered as having pre-existing
died of noncardiovascular events. The relative risk of death
clinical events. All blood samples were obtained afterfrom CAD was 0.71 in HD patients with a Lp(a) concentration
an overnight fast before heparinization or initiation ofabove 30 mg/dl.
Conclusions. This study indicates that the serum Lp(a) levels HD. Serum Lp(a) concentrations were measured by en-
are independent indicators of the future risk of death from zyme-linked immunosorbent assay.
CAD in HD patients. The causes of death during the five-year follow-up
period were classified into either cardiovascular or non-
cardiovascular events. Cardiovascular events were cere-
Lipoprotein(a) [Lp(a)] is a cholesterol-rich lipoprotein brovascular disease (CVD), CAD, and aneurysmal rup-
with structural similarities to low-density lipoprotein ture. Noncardiovascular events included malignancies
(LDL) and contains apolipoprotein (a) [apo (a)], which
and infectious and other miscellaneous diseases.
is a glycoprotein with sequence homology to plasmino-
Values were expressed by means 6 sd. Difference was
gen [1]. Lp(a) was considered as an independent risk
evaluated by a nonpaired t-test and a chi-squared test.factor for cardiovascular events in the general population
Cox regression analyses were used to detect the indepen-[2]. Although an elevated concentration of Lp(a) levels
dent variables that could influence the death from CAD.in hemodialysis (HD) patients has been reported [3], it
is still not clear whether Lp(a) plays a key role in the
occurrence of cardiovascular events in HD patients. This RESULTS
study was done so as to clarify the role of serum Lp(a) Follow-up and clinical events
on the fatal cardiovascular events, especially coronary
Among 268 HD patients, 70 patients (26.1%) diedartery disease (CAD) in patients with HD treatment.
during the five-year observation period (Table 1). Forty
nine of them (70.0%) were by cardiovascular and the
METHODS remaining 21 (30.0%) were by noncardiovascular events.
From 1992 to 1997, we investigated the prognosis in Among 49 patients who died of cardiovascular events,
268 HD patients (153 male and 115 female, mean age 26, 22, and 1 were CVD, CAD, and aneurysmal rupture
of thoracic aorta, respectively. Of 22 patients who died of
CAD, congestive heart failure caused by old myocardialKey words: cardiovascular disease, diabetic nephropathy, glomerulo-
nephritis. infarction and myocardial infarction accounted for 7 and
15, respectively. 1999 by the International Society of Nephrology
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Table 2. Multiple logistic regression analysis of risk factors for deathTable 1. Causes of death in hemodialysis patients
due to coronary artery disease in HD patients
Clinical event N
Variable Relative risk
Cardiovascular event
Cerebrovascular disease 26 Gender male 0.47
Age years 20.02Cerebral hemorrhage (15)
Cerebral infarction (7) Duration of HD months 20.01
Smoking 0.23Subarachinoid hemorrhage (4)
Coronary artery disease 22 TC 220 mg/dl , 20.44
HDL-C 40 mg/dl . 20.17Congestive heart failure due to old myocardial infarction (7)
Myocardial infarction (15) Lp(a) 30 mg/dl , 0.71a
Diabetic nephropathy 0.50Aneurysmal rupture 1
Noncardiovascular event Abbreviations are: HD, hemodialysis; TC, total cholesterol; HDL-C, high
Malignant disease 9 density lipoprotein cholesterol; Lp(a), lipoprotein(a).
Gastric cancer (2) a P , 0.05
Colon cancer (5)
Lung cancer (1)
Prostate cancer (1)
Infectious disease 8
Pneumonia (4) normal subjects (12.3%) [4]. During the five-year obser-
Sepsis (3)
vation period, 70 HD patients (26.1%) died. AmongPeritonitis (1)
Miscellaneous disease 4 the 70 deaths, 49 of them died of cardiovascular events.
Cachexia (4) Among 49 HD patients who died of cardiovascular
events, 26 and 22 were CVD and CAD, respectively.
The clinical characteristics of HD patients who died of
CAD were patients with DN, less female gender andCharacteristics of hemodialysis patients who died of
high Lp(a) levels compared with those who died of CVD.cardiovascular events
From the multiple logistic regression analysis of risk fac-
Compared with HD patients who died of noncardio- tors for death caused by CAD, it is suggested that the
vascular events, those who died of cardiovascular events
Lp(a) level is an independent risk factor for CAD. Con-
had characteristics of a large number of DN patients, a
sidering these results, the use of effective pharmacologi-long-term HD period, and higher Lp(a) levels [Lp(a)
cal agents such as nicotinic acid and/or LDL apheresiswas 29.3 6 22.0 mg/dl in patients with cardiovascular
to reduce Lp(a) levels in HD patients will provide theevents (N 5 49) vs. 19.5 6 13.8 mg/dl in patients without
opportunity to test the hypothesis that Lp(a) is a modifi-cardiovascular events, (N 5 21), P , 0.05].
able risk factor for the death of CAD in HD patients.
Lipoprotein(a) is a lipoprotein that has apo B-100 andCharacteristics of hemodialysis patients who died of
apo (a) as an apolipoprotein that has high homologycoronary artery disease
with plasminogen [1]. It has recently been proposed thatCompared with HD patients who died of CVD, those
Lp(a) is atherogenic lipoprotein. The proposed mecha-who died of CAD had characteristics of old age, male
nisms are as follows. First, Lp(a) interfered with severalgender, and higher Lp(a) levels [Lp(a) was 34.4 6 19.0
steps in the clotting and fibrinolysis cascade [5]. Second,mg/dl in CAD (N 5 22) vs. 22.4 6 18.6 mg/dl in CVD
the cholesterol content of Lp(a) is low compared with(N 5 26), P , 0.05].
LDL, but oxidized Lp(a) deposit easily and stay in the
Analysis of risk factors for death from coronary artery arterial walls for a longer period [6]. Third, Lp(a) pro-
disease in hemodialysis patients motes proliferation of smooth muscle cells by inhibiting
Male gender, age, duration of HD, smoking, high total plasminogen, which, in turn, reduces the activation of
cholesterol, low high-density lipoprotein cholesterol lev- transforming growth factor-b, an inhibitor of cell prolif-
els, and DN were independent contributors to the in- eration [7]. With such reports, together with this study,
creased risk of CAD mortality (Table 2). Baseline Lp(a) it is reasonable to conclude that high Lp(a) levels may
levels higher than 30 mg/dl were the sole independent contribute to coronary artery sclerosis in HD patients.
risk factors by multiple logistic regression analysis (rela- In summary, we suggest that HD patients with higher
tive risk, 0.71). Lp(a) levels have more of a chance of death from cardio-
vascular events, especially CAD, and therefore, careful
observations are needed in these patients. We shouldDISCUSSION
strictly manage not only Lp(a) levels, but also other riskLipoprotein(a) levels above 30 mg/dl are considered
factors in all HD patients with higher Lp(a) levels.to be high according to our previous report [4]. The
number of 268 HD patients with high Lp(a) levels was Reprint requests to Hiroshige Ohashi, M.D., Division of Nephrology,
Prefectural Gifu Hospital, 4-6-1 Noishiki, Gifu 500-8717, Japan.96 (35.8%). This is significantly higher than that seen in
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